Bayer Aktienges ADR (BAYRY)

$7.63 +0.05 (0.66%)
Market Cap 29.90B
Revenue (ttm) 50.43B
Net Income (ttm) -2.76B
EPS (ttm) N/A
PE Ratio 5.60
Forward PE 5.52
Profit Margin -5.48%
Debt to Equity Ratio 1.26
Volume 421,791
Avg Vol 401,744
Day's Range N/A - N/A
Shares Out 3.93B
Stochastic %K 17%
Beta 0.84
Analysts Sell
Price Target $7.95

Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-c...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 49 214 30 1
Address:
Kaiser-Wilhelm-Allee 1, Leverkusen, Germany
AanoldMcFace
AanoldMcFace Nov. 6 at 12:27 PM
$BAYRY every day this bleeds in EU, not sure why.
1 · Reply
SmallCapAlert
SmallCapAlert Nov. 5 at 3:34 PM
$LTELF Watchlist German Stocks: $LTELF cheapest german company in defense AI Defense solutions https://www.lstelcom.com/en/applications-use-cases/artificial-intelligence-solutions/ Revenue is much higher than the small marketcap. Why is the marketcap so low? Marketcap: $24 million FreeFloat: 1.6 million $BNTX Marketcap: $25 billion $BAYRY Marketpcap: $28 billion $DB Marketcap: $80 billion $RNMBY
0 · Reply
autophagy1
autophagy1 Nov. 4 at 10:17 PM
$BAYRY Just a bit better every day crawling out from under the worst & most dumb acquisition ever-Monsanto.
0 · Reply
11thestate
11thestate Nov. 3 at 11:54 PM
If you missed the deadline, don’t miss this update. This is probably the most useful info you’ve read in years about $BAYRY — how you can actually recover something: https://11th.com/cases/bayer-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=stlm&utm_content=11032025
0 · Reply
HereForFunsies
HereForFunsies Nov. 3 at 5:07 PM
$BAYRY needs to say something lol no news in between earnings calls just make this burnout
0 · Reply
HereForFunsies
HereForFunsies Oct. 30 at 3:18 PM
$BAYRY looks like a short into earnings 😩 Please have good numbers this quarter lol
0 · Reply
Quantumup
Quantumup Oct. 30 at 2:07 PM
TD Cowen⬆️the PT on $BBIO to $95 from $60, reiterated at Buy, and said, 'Attruby Beats Expectations Again—BridgeBio Now A Diversified Orphan Co' $ALNY $PFE $AZN $BAYRY TD Cowen added, The 51% Q/Q Attruby sales growth beat expectations and was driven by treatment naïve patients and accelerating new patient prescriptions. BridgeBio remains focused on the Attruby launch and the late-stage pipeline and is 2/2 so far with positive LGMD and ADH1 readouts this week. [👀] We fully expect the achon trial early next year to succeed too. We increased our DCF-based PT to $95, and remain Buy.
0 · Reply
Quantumup
Quantumup Oct. 30 at 10:45 AM
Leerink⬆️ $BBIO's PT to $75 from $68 and reiterated at an Outperform rating. $BAYRY $AZN $ALNY $PFE Here's what Leerink had to say in its note to investors:
0 · Reply
SparkyReturns
SparkyReturns Oct. 29 at 4:28 PM
$ZTS Check out an investing idea: ICU. What if you could buy at a $ 20M Market Cap a company with a TAM in the billions (5-20B), with final study results within 9 months? And, that same medical device already has Humanitarian Device approval for use with children and is being rolled out to the top pediatric hospitals in the country such as Cincinnati, Texas, UM CS Mott, CHOP Philly. Prestigious hospitals such as Mayo Clinic, Stanford, Cleveland Clinic are participating in adult study. Plus, the device has 6 Breakthrough Device Designations, and has been shown to reduce mortality by 50% and dialysis dependency by almost 100% in patients with AKI and sepsis. Has obtained multiple grants from FDA and Dept of Defense. Stock was knocked down recently when DSMB wanted to increase size of study from 200 to 339. That caught retail off guard and now the stock is a screaming bargain. Zero debt. Pediatric revenue ramping. Ample cash runway to profit. $TAK $BAYRY $SDZXF $TEVA
0 · Reply
PatNeville
PatNeville Oct. 21 at 7:54 PM
$BAYRY Talking longevity drugs with Andy Lee of Vincere Biosciences on the HEAT Podcast. https://www.youtube.com/watch?v=5kQ732nH4cU
0 · Reply
Latest News on BAYRY
No data available.
AanoldMcFace
AanoldMcFace Nov. 6 at 12:27 PM
$BAYRY every day this bleeds in EU, not sure why.
1 · Reply
SmallCapAlert
SmallCapAlert Nov. 5 at 3:34 PM
$LTELF Watchlist German Stocks: $LTELF cheapest german company in defense AI Defense solutions https://www.lstelcom.com/en/applications-use-cases/artificial-intelligence-solutions/ Revenue is much higher than the small marketcap. Why is the marketcap so low? Marketcap: $24 million FreeFloat: 1.6 million $BNTX Marketcap: $25 billion $BAYRY Marketpcap: $28 billion $DB Marketcap: $80 billion $RNMBY
0 · Reply
autophagy1
autophagy1 Nov. 4 at 10:17 PM
$BAYRY Just a bit better every day crawling out from under the worst & most dumb acquisition ever-Monsanto.
0 · Reply
11thestate
11thestate Nov. 3 at 11:54 PM
If you missed the deadline, don’t miss this update. This is probably the most useful info you’ve read in years about $BAYRY — how you can actually recover something: https://11th.com/cases/bayer-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=stlm&utm_content=11032025
0 · Reply
HereForFunsies
HereForFunsies Nov. 3 at 5:07 PM
$BAYRY needs to say something lol no news in between earnings calls just make this burnout
0 · Reply
HereForFunsies
HereForFunsies Oct. 30 at 3:18 PM
$BAYRY looks like a short into earnings 😩 Please have good numbers this quarter lol
0 · Reply
Quantumup
Quantumup Oct. 30 at 2:07 PM
TD Cowen⬆️the PT on $BBIO to $95 from $60, reiterated at Buy, and said, 'Attruby Beats Expectations Again—BridgeBio Now A Diversified Orphan Co' $ALNY $PFE $AZN $BAYRY TD Cowen added, The 51% Q/Q Attruby sales growth beat expectations and was driven by treatment naïve patients and accelerating new patient prescriptions. BridgeBio remains focused on the Attruby launch and the late-stage pipeline and is 2/2 so far with positive LGMD and ADH1 readouts this week. [👀] We fully expect the achon trial early next year to succeed too. We increased our DCF-based PT to $95, and remain Buy.
0 · Reply
Quantumup
Quantumup Oct. 30 at 10:45 AM
Leerink⬆️ $BBIO's PT to $75 from $68 and reiterated at an Outperform rating. $BAYRY $AZN $ALNY $PFE Here's what Leerink had to say in its note to investors:
0 · Reply
SparkyReturns
SparkyReturns Oct. 29 at 4:28 PM
$ZTS Check out an investing idea: ICU. What if you could buy at a $ 20M Market Cap a company with a TAM in the billions (5-20B), with final study results within 9 months? And, that same medical device already has Humanitarian Device approval for use with children and is being rolled out to the top pediatric hospitals in the country such as Cincinnati, Texas, UM CS Mott, CHOP Philly. Prestigious hospitals such as Mayo Clinic, Stanford, Cleveland Clinic are participating in adult study. Plus, the device has 6 Breakthrough Device Designations, and has been shown to reduce mortality by 50% and dialysis dependency by almost 100% in patients with AKI and sepsis. Has obtained multiple grants from FDA and Dept of Defense. Stock was knocked down recently when DSMB wanted to increase size of study from 200 to 339. That caught retail off guard and now the stock is a screaming bargain. Zero debt. Pediatric revenue ramping. Ample cash runway to profit. $TAK $BAYRY $SDZXF $TEVA
0 · Reply
PatNeville
PatNeville Oct. 21 at 7:54 PM
$BAYRY Talking longevity drugs with Andy Lee of Vincere Biosciences on the HEAT Podcast. https://www.youtube.com/watch?v=5kQ732nH4cU
0 · Reply
ElJoe
ElJoe Oct. 17 at 7:32 PM
$BAYRY @HereForFunsies Masterly to trade into BKNG. In the middle of one of the all-time great bull markets, this stock has been in the toilet and basically gone nowhere in God-knows-how-many years. Still trading at 50% of 2020 value, and 20% of Pre-Monsanto value.
1 · Reply
11thestate
11thestate Oct. 17 at 1:32 PM
$BAYRY has agreed to a $38M settlement to resolve claims that it misled investors about its due diligence in acquiring Monsanto and the legal risks tied to Roundup-related litigation. Who’s eligible? Anyone who purchased $BAYRY shares between May 23, 2016, and July 6, 2020. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.23 — but if only ~25% of eligible investors file, the effective payout could increase to $0.92. Can I still file? Yes — claims are currently being accepted, including late claims, until October 16, 2025. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/bayer-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=faq&utm_content=10162025_1
0 · Reply
PremarketAnalysis
PremarketAnalysis Oct. 16 at 2:47 PM
$BAYRY SignalEngine: MM Infl (Bullish), Algo Vol 64%, Org Vol 36%, BRX 0%, Res 8.7, Sup 7.81 Algo Int: Absorbing pressure for reversal push.. watch for upward push as liquidity shifts over the next 5 to 7 sessions based on current 2-hour compression/volume rhythm Momentum Feed: https://premarketanalysis.com/#momentum=BAYRY
0 · Reply
HereForFunsies
HereForFunsies Oct. 16 at 11:57 AM
$BAYRY
0 · Reply
PremarketAnalysis
PremarketAnalysis Oct. 9 at 7:12 PM
$BAYRY fading after brief reclaim. SignalEngine: Bearish 38/62, Algo Vol 21%, Org Vol 78%, BRX 0%. Algo Intent: spoofing tape to stall price action..synthetic flow detected. Momentum Feed: premarketanalysis.com/#momentum=BAYRY
1 · Reply
11thestate
11thestate Oct. 9 at 6:42 PM
$BAYRY has agreed to a $38M settlement with $BAYRY investors to resolve claims it misled them about its due diligence in acquiring Monsanto and the legal risks tied to Roundup-related litigation. The filing deadline is October 16, 2025. If you bought $BAYRY between May 23, 2016, and July 6, 2020, you can file for payment here: https://11th.com/cases/bayer-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=ddl&utm_content=10092025_1
0 · Reply
ZacksResearch
ZacksResearch Oct. 9 at 3:39 PM
$BAYRY takes aim at KRAS — one of cancer’s toughest targets. Bayer and Kumquat just kicked off a Phase I study for KQB548, focused on KRAS G12D-mutated tumors including pancreatic, colorectal, and lung cancers — a major step into precision oncology. Full details on the trial and scope here 👉 https://www.zacks.com/stock/news/2765555/bayry-begins-phase-i-study-with-kqb548-in-kras-mutated-cancers?cid=sm-stocktwits-2-2765555-teaser-15384&ADID=SYND_STOCKTWITS_TWEET_2_2765555_TEASER_15384
0 · Reply
ZacksResearch
ZacksResearch Oct. 9 at 2:39 PM
$BAYRY up 62.5% YTD — impressive performance! 🚀 The phase I study for KQB548, targeting KRAS G12D-mutated tumors, marks a big leap in cancer treatment. Plus, Bayer's pipeline is booming with cell and gene therapies, bolstered by acquisitions. Discover the full story here 👉 https://www.zacks.com/stock/news/2765555/bayry-begins-phase-i-study-with-kqb548-in-kras-mutated-cancers?cid=sm-stocktwits-2-2765555-body-15368&ADID=SYND_STOCKTWITS_TWEET_2_2765555_BODY_15368
0 · Reply
ZacksResearch
ZacksResearch Oct. 8 at 5:15 PM
$BAYRY’s BlueRock just delivered strong 36-month results 🧠 Bemdaneprocel continues to show safety and lasting improvement in motor symptoms for Parkinson’s patients — a major validation for this cell therapy approach. See the full data readout here 👉 https://www.zacks.com/stock/news/2764774/bayer-reports-positive-data-on-cell-therapy-for-parkinsons-disease?cid=sm-stocktwits-2-2764774-teaser-15234&ADID=SYND_STOCKTWITS_TWEET_2_2764774_TEASER_15234
0 · Reply
ZacksResearch
ZacksResearch Oct. 8 at 4:15 PM
$BAYRY's positive 36-month data for bemdaneprocel in Parkinson's disease shows it's well-tolerated with no adverse events. 💡 🚀 Year to date, shares have surged over 64%, outpacing a 10% industry decline. Discover BAYRY’s promising pipeline here 👉 https://www.zacks.com/stock/news/2764774/bayer-reports-positive-data-on-cell-therapy-for-parkinsons-disease?cid=sm-stocktwits-2-2764774-body-15233&ADID=SYND_STOCKTWITS_TWEET_2_2764774_BODY_15233
0 · Reply
SpinningRims
SpinningRims Oct. 8 at 2:32 PM
$BAYRY Why the historical downtrend?
1 · Reply
ZacksResearch
ZacksResearch Oct. 8 at 1:13 PM
Pharma rebound in motion — are $NVS, $JNJ, or $BAYRY your next big win? 💊 Pfizer’s landmark pricing deal with Trump is lighting up the drug sector, with Johnson & Johnson, Bayer, and Novartis now looking like prime portfolio contenders. Discover which of these pharma giants could lead the next leg higher 👉 https://www.zacks.com/stock/news/2764279/3-large-drug-stocks-to-watch-as-industry-recovers-after-pfe-trump-deal?cid=sm-stocktwits-2-2764279-teaser-15073&ADID=SYND_STOCKTWITS_TWEET_2_2764279_TEASER_15073
0 · Reply